Last reviewed · How we verify
Experimental drug 9MW1911
At a glance
| Generic name | Experimental drug 9MW1911 |
|---|---|
| Sponsor | Mabwell (Shanghai) Bioscience Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- An Evaluation of 9MW1911 Injection in Healthy Subjects (PHASE1)
- A Clinical Study in Healthy Subjects to Evaluate 9MW1911 Injection (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Experimental drug 9MW1911 CI brief — competitive landscape report
- Experimental drug 9MW1911 updates RSS · CI watch RSS
- Mabwell (Shanghai) Bioscience Co., Ltd. portfolio CI